-
Je něco špatně v tomto záznamu ?
Pharmacokinetics of dasatinib
J. Hořínková, M. Šíma, O. Slanař
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
SVV 260373
Univerzita Karlova v Praze
NLK
Directory of Open Access Journals
od 2012
Medline Complete (EBSCOhost)
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
- MeSH
- chemorezistence MeSH
- chronická myeloidní leukemie farmakoterapie metabolismus MeSH
- dasatinib farmakokinetika terapeutické užití MeSH
- inhibitory proteinkinas farmakokinetika terapeutické užití MeSH
- koncentrace vodíkových iontů MeSH
- lidé MeSH
- systém (enzymů) cytochromů P-450 MeSH
- žaludeční kyselina MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many cases where other agents bring no improvement due to resistance. Pharmacokinetics of dasatinib has specific characteristics that may play an important role in achieving sufficient exposure in patients. Therefore, the key pharmacokinetic properties are summarized in this report. For example, dasatinib absorption is significantly influenced by gastric pH and its modulation can be a source of serious interactions, as well as simultaneous administration of drugs affecting cytochrome P450.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19039715
- 003
- CZ-PrNML
- 005
- 20191118082435.0
- 007
- ta
- 008
- 191111s2019 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/23362936.2019.10 $2 doi
- 035 __
- $a (PubMed)31586504
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hořínková, Jana $7 xx0241951 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 245 10
- $a Pharmacokinetics of dasatinib / $c J. Hořínková, M. Šíma, O. Slanař
- 520 9_
- $a Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many cases where other agents bring no improvement due to resistance. Pharmacokinetics of dasatinib has specific characteristics that may play an important role in achieving sufficient exposure in patients. Therefore, the key pharmacokinetic properties are summarized in this report. For example, dasatinib absorption is significantly influenced by gastric pH and its modulation can be a source of serious interactions, as well as simultaneous administration of drugs affecting cytochrome P450.
- 650 _2
- $a systém (enzymů) cytochromů P-450 $7 D003577
- 650 _2
- $a dasatinib $x farmakokinetika $x terapeutické užití $7 D000069439
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a žaludeční kyselina $7 D005744
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a chronická myeloidní leukemie $x farmakoterapie $x metabolismus $7 D015464
- 650 _2
- $a inhibitory proteinkinas $x farmakokinetika $x terapeutické užití $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Šíma, Martin $7 xx0222901 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $7 xx0058262 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 773 0_
- $w MED00013414 $t Prague medical report $x 1214-6994 $g Roč. 120, č. 2-3 (2019), s. 52-63
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31586504 $y Pubmed
- 856 41
- $u https://pmr.lf1.cuni.cz/media/pdf/pmr_2019120020052.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 7 $c 1071 $y a $z 0
- 990 __
- $a 20191111 $b ABA008
- 991 __
- $a 20191118082715 $b ABA008
- 999 __
- $a ok $b bmc $g 1464685 $s 1078309
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 120 $c 2-3 $d 52-63 $e - $i 1214-6994 $m Prague Medical Report $n Prague Med. Rep. $x MED00013414
- GRA __
- $a SVV 260373 $p Univerzita Karlova v Praze
- LZP __
- $b NLK118 $a Pubmed-20191111
